Companies

Taro’s upbeat performance perks up Sun Pharma

Nalinakanthi V BL Research Bureau | Updated on March 12, 2018 Published on February 09, 2013




Strong growth in the US led by Taro Pharma (25 per cent) and anti-cancer drug Lipidox sales (on temporary importation permission), combined with a favourable currency movement helped Sun Pharma post a robust 34 per cent year-on-year revenue growth in the December quarter. Taro’s upbeat performance was driven by price increases in select products which more than compensated for the volume decline.

Sun’s India formulations segment grew 13 per cent during the quarter. The growth seems lacklustre due to change in the accounting of discounts and sales return. Discounts and returns which were earlier treated as expenses have now been adjusted against sales. Adjusting for this, the domestic sales grew at a healthy 19 per cent ahead of the industry. Both operating profit and net profit grew 32 per cent – despite an increase in tax outgo.

Acquisitions completed

During the quarter, Sun achieved financial closure of its two US acquisitions – specialty dermatology company DUSA Pharma and URL Pharma’s generic business (acquired through subsidiary Caraco Pharma).

The URL acquisition will provide it access to 107 products and 230 ANDA (Abbreviated New Drug Application) filings. Sun’s management is hopeful of achieving robust volume growth from URL’s existing pipeline by improving productivity and tightening costs.

Merger terminated

The company recently terminated the merger agreement announced last year to acquire the balance 34 per cent stake in Taro Pharma for $39.5 per share. Sun Pharma currently owns 66 per cent stake in Taro. Considering the run up in Taro’s stock price to $51, Sun Pharma concluded that Taro shareholders may not be willing to approve the merger unless the offer price was increased substantially. With cash in excess of Rs 6,500 crore, Sun is exploring inorganic growth opportunities in the US and other emerging markets.

Sun, until recently, was given temporary importation permission to sell J&J’s anti-cancer drug Doxil’s equivalent (sold as Lipidox by Sun) in the US. But its generic filing for the same product was recently approved by the US FDA. With no other approved supplier, this may be an interesting opportunity for Sun over at least one year.

> nalinakanthi.v@thehindu.co.in

Published on February 09, 2013

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
null
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.